Am J Psychiatry 159:469-473, March 2002
© 2002 American Psychiatric Association
Are Subjects in Pharmacological Treatment Trials of Depression Representative of Patients in Routine Clinical Practice?
Mark Zimmerman, M.D.,
Jill I. Mattia, Ph.D., and
Michael A. Posternak, M.D.
OBJECTIVE: The methods used to evaluate the efficacy of antidepressants differ from treatment for depression in routine clinical practice. The rigorous inclusion/exclusion criteria used to select subjects for participation in efficacy studies potentially limit the generalizability of these trials’ results. It is unknown how much impact these criteria have on the representativeness of subjects in efficacy trials. This study estimated the proportion of depressed patients treated in routine clinical practice who would meet standard inclusion/exclusion criteria for an efficacy trial. METHOD: A total of 803 individuals, aged 16–65 years, who were seen at intake at an outpatient practice underwent a thorough diagnostic evaluation, including the administration of semistructured diagnostic interviews; 346 patients had current major depression. Common inclusion/exclusion criteria used in efficacy studies of antidepressants were applied to the depressed patients to determine how many would have qualified for an efficacy trial. RESULTS: Approximately one-sixth of the 346 depressed patients would have been excluded from an efficacy trial because they had a bipolar or psychotic subtype of depression. The presence of a comorbid anxiety or substance use disorder, insufficient severity of depressive symptoms, or current suicidal ideation would have excluded 86.0% (N=252) of the remaining 293 outpatients with nonpsychotic unipolar major depressive disorder from an antidepressant efficacy trial. CONCLUSIONS: Subjects treated in antidepressant trials represent a minority of patients treated for major depression in routine clinical practice. These results show that antidepressant efficacy trials tend to evaluate a subset of depressed individuals with a specific clinical profile.
This article has been cited by other articles:
|
|
|
|
 
H. Gardarsdottir, T. C. Egberts, J. J. Stolker, and E. R. Heerdink
Duration of Antidepressant Drug Treatment and Its Influence on Risk of Relapse/Recurrence: Immortal and Neglected Time Bias
Am. J. Epidemiol.,
June 4, 2009;
(2009)
kwp142v1.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Wisniewski, A. J. Rush, A. A. Nierenberg, B. N. Gaynes, D. Warden, J. F. Luther, P. J. McGrath, P. W. Lavori, M. E. Thase, M. Fava, et al.
Can Phase III Trial Results of Antidepressant Medications Be Generalized to Clinical Practice? A STAR*D Report
Am J Psychiatry,
May 1, 2009;
166(5):
599 - 607.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Anderson, I. Ferrier, R. Baldwin, P. Cowen, L Howard, G Lewis, K Matthews, R. McAllister-Williams, R. Peveler, J Scott, et al.
Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines
J Psychopharmacol,
June 1, 2008;
22(4):
343 - 396.
[Abstract]
[PDF]
|
|
|
|
|
|
|
D. Deshauer MD MSc, D. Moher PhD, D. Fergusson PhD, E. Moher BA, M. Sampson MLIS, and J. Grimshaw MD PhD
Selective serotonin reuptake inhibitors for unipolar depression: a systematic review of classic long-term randomized controlled trials
Can. Med. Assoc. J.,
May 6, 2008;
178(10):
1293 - 1301.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Blumenthal, M. A. Babyak, P. M. Doraiswamy, L. Watkins, B. M. Hoffman, K. A. Barbour, S. Herman, W. E. Craighead, A. L. Brosse, R. Waugh, et al.
Exercise and Pharmacotherapy in the Treatment of Major Depressive Disorder
Psychosom Med,
September 1, 2007;
69(7):
587 - 596.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Costantino, E. Ceriani, A. M. Rusconi, and N. Montano
Eligibility Criteria of Randomized Controlled Trials
JAMA,
July 4, 2007;
298(1):
39 - 39.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. H. Dworkin, J. Katz, and M. J. Gitlin
Placebo response in clinical trials of depression and its implications for research on chronic neuropathic pain
Neurology,
December 29, 2005;
65(12_suppl_4):
S7 - S19.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zimmerman, I. Chelminski, and M. A. Posternak
Generalizability of Antidepressant Efficacy Trials: Differences Between Depressed Psychiatric Outpatients Who Would or Would Not Qualify for an Efficacy Trial
Am J Psychiatry,
July 1, 2005;
162(7):
1370 - 1372.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. L. Hackett, C. S. Anderson, and A. O. House
Management of Depression After Stroke: A Systematic Review of Pharmacological Therapies
Stroke,
May 1, 2005;
36(5):
1092 - 1097.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. A. Nierenberg, P. Eidelman, Y. Wu, and M. Joseph
Depression: An Update for the Clinician
Focus,
January 1, 2005;
3(1):
3 - 12.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Leon, D. A. Solomon, T. I. Mueller, J. Endicott, J. P. Rice, J. D. Maser, W. Coryell, and M. B. Keller
A 20-Year Longitudinal Observational Study of Somatic Antidepressant Treatment Effectiveness
Focus,
January 1, 2005;
3(1):
106 - 113.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Khan, R. L. Kolts, M. E. Thase, K. R. R. Krishnan, and W. Brown
Research Design Features and Patient Characteristics Associated With the Outcome of Antidepressant Clinical Trials
Am J Psychiatry,
November 1, 2004;
161(11):
2045 - 2049.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Lebowitz
Clinical Trials in Late Life: New Science in Old Paradigms
Gerontologist,
August 1, 2004;
44(4):
452 - 458.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zimmerman, M. Posternak, M. Friedman, N. Attiullah, S. Baymiller, R. Boland, S. Berlowitz, S. Rahman, K. Uy, and S. Singer
Which Factors Influence Psychiatrists' Selection of Antidepressants?
Am J Psychiatry,
July 1, 2004;
161(7):
1285 - 1289.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. R. Heerdink, J. J. Stolker, W. E. E. Meijer, G. W. K. Hugenholtz, and A. C. G. Egberts
Need for medicine-based evidence in pharmacotherapy
The British Journal of Psychiatry,
May 1, 2004;
184(5):
452 - 452.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Herxheimer and B. Mintzes
Antidepressants and adverse effects in young patients: uncovering the evidence
Can. Med. Assoc. J.,
February 17, 2004;
170(4):
487 - 489.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Parker, I. M. Anderson, and P. Haddad
Clinical trials of antidepressant medications are producing meaningless results
The British Journal of Psychiatry,
August 1, 2003;
183(2):
102 - 104.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Y.H. Kim and R. G. Holloway
Burdens and Benefits of Placebos in Antidepressant Clinical Trials: A Decision and Cost-Effectiveness Analysis
Am J Psychiatry,
July 1, 2003;
160(7):
1272 - 1276.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Leon, D. A. Solomon, T. I. Mueller, J. Endicott, J. P. Rice, J. D. Maser, W. Coryell, and M. B. Keller
A 20-Year Longitudinal Observational Study of Somatic Antidepressant Treatment Effectiveness
Am J Psychiatry,
April 1, 2003;
160(4):
727 - 733.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. M. Anderson
Drug treatment of depression: reflections on the evidence
Advan. Psychiatr. Treat.,
January 1, 2003;
9(1):
11 - 20.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. K. Graham, A. K. Wutoh, R. D. Wutoh, J. P. Hampson, J. N. Harvey, S. A. Goldman, P. J. Greene, T. J. La Vaque, K. E. Lasser, S. J. Woolhandler, et al.
Postmarketing Surveillance and Black Box Warnings
JAMA,
August 28, 2002;
288(8):
955 - 959.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Antidepressants: Study Subjects Aren't Like Other Patients
Journal Watch Psychiatry,
June 19, 2002;
2002(619):
14 - 14.
[Full Text]
|
|
|
|
|
|
|
Antidepressants: Study Subjects Aren't Like Other Patients
Journal Watch Women's Health,
May 8, 2002;
2002(508):
4 - 4.
[Full Text]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2002
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
